News Sentiment

BIO sentiment intelligence

Bio-Rad Laboratories Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 51 Balanced news tone 50 relevant articles
Exchange NYSE United States
Sector Healthcare Market context
Industry Medical Devices Read-through group
Latest close 296.11 Week of 10 Jul 2026
Weighted tone 51/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Earnings

75/100 classification confidence.

Company focus 40

directly relevant articles

Source quality 1

high-authority source matches

Trend context Trend inactive

-0.3% over one week, +3.6% over four weeks, trend inactive, and near fair-value range.

Latest direct headline Neutral

Entera Bio (NASDAQ: ENTX) CEO swaps cash for stock-settled RSUs

Market Reaction

Balanced read

47/100 confidence

News tone and price action are not far from neutral.

Primary event Earnings 75/100 classification
One-week reaction -0.3% Price digesting
Trend fit Trend inactive 3.6% over four weeks
Fair value -2.6% Near fair-value range

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 9
Neutral 33
Negative 8

Relevance

Why the article matched

Direct first
Direct company coverage 40
Industry context 10
Sector context 0

Sources

Coverage mix

Publishers
Market source 12
Sahm 11
Stock Titan 6
TradingView 6
StockStory 3
Stock Traders Daily 3
ad-hoc-news.de 2
FinancialContent 2

Event Lens

What the news is about

Classified themes
Earnings 23
Market update 14
Deals and strategy 4
Balance sheet 3
Analyst action 3
Guidance 3

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 31-50 of 50
Sahm Direct company coverage

A Look At Bio-Rad (BIO) Valuation After Q1 2026 Net Loss And Outlook Cut

Bio-Rad Laboratories (BIO) experienced a Q1 2026 net loss of US$527.1 million and reduced revenue outlook, yet Simply Wall St's analysis suggests the stock is 19.9% undervalued with a fair value of $321.25. This valuation is based on expected growth in molecular diagnostics and p

Tone
Negative 39/100
Event
Earnings
Published
10 May 2026 23:40
Source
Sahm
StocksToTrade Direct company coverage

Bio-Rad Laboratories Inc. Class A (BIO) Stock Price | Live Quotes & Charts | NYSE

This page provides live quotes and charts for Bio-Rad Laboratories Inc. Class A (BIO) stock on the NYSE, showing a current price of $254.32, down $3.00 (-1.17%). It notes that there are no analyst ratings or earnings information currently available for the company. The page also

Tone
Neutral 50/100
Event
Earnings
Published
08 May 2026 23:39
Source
StocksToTrade
FinancialContent Direct company coverage

Bio-Rad Laboratories, Inc. Class A Common Stock (NY: BIO

This article provides a list of recent news and press releases concerning Bio-Rad Laboratories, Inc. (NYSE: BIO), including financial results disclosures, management changes, and conference participation announcements. It covers events from early 2023 through mid-2024, highlighti

Tone
Neutral 50/100
Event
Earnings
Published
06 May 2026 14:39
Source
FinancialContent
Sahm Direct company coverage

Bio Rad Laboratories (BIO) EPS Loss Revives Concerns Over Volatile Profit Narratives

Bio-Rad Laboratories (BIO) reported a Q1 2026 basic EPS loss of US$19.55, despite an increase in quarterly revenue. This volatility in earnings, with net income swinging from a US$720 million gain to a US$527 million loss, raises concerns about the company's profit stability. Whi

Tone
Neutral 50/100
Event
Earnings
Published
03 May 2026 14:39
Source
Sahm
Sahm Direct company coverage

Bio-Rad Weighs 2026 Outlook As Middle East Headwinds Meet Stilla Hopes

Bio-Rad Laboratories (NYSE:BIO) has issued a cautious revenue outlook for 2026, citing a material impact from geopolitical disruptions in the Middle East, which led to a quarterly net loss of US$527.1 million despite sales being in line with guidance. The company plans to counter

Tone
Negative 39/100
Event
Guidance
Published
01 May 2026 08:39
Source
Sahm
Quiver Quantitative Direct company coverage

Bio-Rad Laboratories (BIO) Releases Q1 2026 Earnings: Revenue Up Slightly, EPS Deeply Negative on Large GAAP Loss

Bio-Rad Laboratories (BIO) reported Q1 2026 revenue of $592.1 million, a 1.1% increase year-over-year, and a strong operating profit increase. Despite improved operating performance and cash flow, the company posted a deeply negative diluted EPS of -19.55 due to a large GAAP net

Tone
Negative 29/100
Event
Earnings
Published
30 Apr 2026 21:30
Source
Quiver Quantitative
Sahm Direct company coverage

Transcript: Bio-Rad Laboratories Q1 2026 Earnings Conference Call

Bio-Rad Laboratories reported a 1.1% increase in net sales for Q1 2026, but a 4.2% decrease on a currency-neutral basis, primarily due to geopolitical conflicts in the Middle East and challenges in academic funding. The company adjusted its full-year 2026 guidance to between -3%

Tone
Negative 40/100
Event
Earnings
Published
30 Apr 2026 20:10
Source
Sahm
Stock Titan Direct company coverage

Bio-Rad (BIO) EVP Courtney Enloe gains shares via RSU vesting, withholds for taxes

Bio-Rad Laboratories' EVP and General Counsel, Courtney C. Enloe, acquired 186 shares of Class A common stock through the vesting of restricted stock units (RSUs) on April 24, 2026. She subsequently had 77 shares withheld to cover tax obligations. After these transactions, her di

Tone
Neutral 50/100
Event
Market update
Published
28 Apr 2026 16:10
Source
Stock Titan
Stock Titan Direct company coverage

Bio-Rad (NYSE: BIO) CFO nets more shares after RSU vesting and tax withholding

Bio-Rad Laboratories' EVP and CFO Roop Kalyan Lakkaraju acquired 1,078 shares of Class A common stock through RSU vesting on April 24, 2026. To cover tax obligations, 420 shares were disposed of at $287.84 per share, resulting in a net increase in direct holdings. After these tra

Tone
Neutral 50/100
Event
Market update
Published
28 Apr 2026 16:10
Source
Stock Titan